Waters partners with Labcorp to expand access to cervical cancer screening
WAT•Waters partnered with Labcorp to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide network beginning in late 2026. Labcorp plans to offer clinician-collected and self-collected screening options through clinics, patient service centers and at home.
1. Screening access expansion
Labcorp intends to offer clinician-collected and self-collected screening options in clinics, its patient service centers and at home beginning in late 2026. Its network serves more than 850,000 physicians and healthcare providers and includes more than 2,200 patient service centers.
2. Assay details
The BD Onclarity HPV Assay is FDA-approved and supports all ASCCP Enduring Risk-Based Management Guidelines through comprehensive extended genotyping.
